Ordering Drugs on Someone Else's NPI: The Federal Exposure Behind Ohio's Med Spa License Suspension

An Ohio clinic lost its authority to hold prescription drugs on June 1 after the state pharmacy board found, among other things, that owners had ordered NAD and sermorelin using the National Provider Identifier numbers of nurse practitioners who had not authorized it. One of those APRNs had already resigned. Another was out of the country. The board also alleged the clinic took delivery of two vials represented as BPC-157 from a supplier the board said held none of the U.S. drug distribution or manufacturing credentials the notice identified. The allegations are unproven and the clinic had thirty days to demand a hearing.

Read as a state licensing matter, this is a records-and-storage case. Read the way a federal prosecutor reads it, two of the findings are not administrative at all.

Read as a state licensing matter, this is a records-and-storage case. Read the way a federal prosecutor reads it, two of those findings are not administrative at all. Using another provider's identifier to obtain drugs and buying purported peptides from an unregistered foreign source are the two facts that convert a pharmacy board file into a federal one.

Key Takeaways

• Ohio summarily suspended a combined med spa and chiropractic clinic's Terminal Distributor of Dangerous Drugs license on June 1, 2026 over drug sourcing and prescriber authority allegations.
• Ordering drugs on an unauthorized prescriber's NPI can support charges under 18 U.S.C. § 1028(a)(7) and a consecutive two-year term under 18 U.S.C. § 1028A.
• Receiving purported BPC-157 from a supplier without U.S. credentials implicates 21 U.S.C. § 331 and felony penalties under 21 U.S.C. § 333(a)(2).
• FDA has classified BPC-157 as a Category 2 bulk substance presenting significant safety risks in compounding.
• In Florida the same purchase is a felony under Fla. Stat. § 499.0051, and South Florida is an active federal peptide enforcement district.

What the Ohio Board Actually Found

The Ohio Board of Pharmacy summarily suspended the Terminal Distributor of Dangerous Drugs license held by a Lewis Center clinic on June 1, 2026, following inspections on April 8 and May 27. The board's summary suspension notice, Case No. A-2026-0164, describes a combined chiropractic and med spa practice that employed advanced practice registered nurses for both medical and aesthetic services. The license remains listed as suspended. Spakinect reported the action as a compliance matter for clinic operators.

The allegations fall into two categories. One is regulatory housekeeping: expired multidose vials, refrigerator security, temperature logs, inventory records. Those are fixable, and they are what most operators focus on after an inspection.

The second group is not housekeeping. The board alleged that clinic owners used APRN NPI numbers to order NAD and sermorelin without authorization, including after one of those APRNs resigned and while another was outside the country. It alleged medication was dispensed with no documented prescriber order, that a non-clinician owner gave dosing guidance to a patient who later lost consciousness, and that drugs returned by one patient were later provided to another. It alleged the clinic received two vials represented as BPC-157 on May 13 from a supplier lacking the U.S. distribution or manufacturing credentials identified in the notice.

Those are federal facts wearing a state license number.

A board file is a public record and a fully assembled investigative package. Expired vials and temperature logs are what operators focus on. The NPI orders and the sourcing invoice are what a federal agent reads.

Why the NPI Allegation Is the Dangerous One

An NPI is a means of identification. When someone uses a provider's NPI without authority to obtain prescription drugs, the government has the elements of identification fraud under 18 U.S.C. § 1028(a)(7), and if the orders traveled by phone, portal, or email, wire fraud under 18 U.S.C. § 1343. Where two people participate, 18 U.S.C. § 1349 charges the agreement itself.

Then comes the enhancement that changes every negotiation. 18 U.S.C. § 1028A adds a mandatory two years, consecutive to everything else, when a means of identification is used during and in relation to a listed predicate felony. Judges cannot run it concurrently. Prosecutors know that, which is why the count is charged as leverage as often as on the merits.

There is a real defense, and it is worth knowing early. In Dubin v. United States, the Supreme Court held that § 1028A reaches a means of identification only where its use is at the crux of what makes the conduct criminal, not where the identifier is an ancillary billing or ordering detail. Whether an NPI on a drug order is the crux or the ancillary detail is a live argument, and it is far easier to make to a line prosecutor deciding what to charge than to a jury after indictment.

An order placed on the credentials of a provider who had already resigned, or who was on another continent, is difficult to characterize as an administrative shortcut.

The resignation timeline is the government's best fact and the defense's hardest one. An order placed on the credentials of a provider who had already left, or who was on another continent, is difficult to characterize as an administrative shortcut.

Peptide Sourcing Is the Second Federal Hook

The BPC-157 allegation is the one every med spa operator in the country should read twice. FDA placed BPC-157 in Category 2 of its bulk drug substances evaluation, meaning the agency identified significant safety risks and said it would consider enforcement against compounders using it. It is not an approved drug. FDA's 2026 briefing documents recommending against seven peptides for the 503A bulks list moved in the same direction.

Buying a purported peptide from a supplier without U.S. registration puts the clinic inside the Federal Food, Drug, and Cosmetic Act. Receiving and delivering an unapproved new drug in interstate commerce violates 21 U.S.C. § 331, and 21 U.S.C. § 355 bars introducing a new drug without an approved application. A first FDCA violation is a misdemeanor under 21 U.S.C. § 333(a)(1), which sounds tolerable until you reach subsection (a)(2). With intent to defraud or mislead, the same conduct becomes a three-year felony. Imported material adds 21 U.S.C. § 381 and, in practice, FDA Office of Criminal Investigations rather than a state inspector.

Redispensing medication returned by another patient is its own problem. Once a drug leaves the clinic's control, the government's theory is adulteration under 21 U.S.C. § 351. Add a patient who lost consciousness, and the health care fraud statute at 18 U.S.C. § 1347 becomes live if any federal payer or false representation touched the file.

Florida Is Not the Safer Address

Operators in Boca Raton, Fort Lauderdale, and Miami should not read an Ohio dateline as distance. Fla. Stat. § 499.0051 makes it a felony to knowingly purchase or receive a prescription drug from a person not authorized to distribute it, and Florida's Drug and Cosmetic Act reaches the receiving clinic, not just the seller. Practicing beyond licensed scope runs through Fla. Stat. § 456.065, a third-degree felony that becomes a second-degree felony when unlicensed practice causes serious bodily injury.

The Southern District of Florida is one of the more active districts in the country on compounded drug and peptide enforcement, and the state Department of Health refers to it. A Florida clinic with this fact pattern would likely see the licensing action and the federal inquiry running at once, which is a materially harder problem than either alone.

What Operators Get Wrong in the First Month

Treating the board case as the whole case. A board file is a public record and a fully assembled investigative package. Federal agents read them. Answering the board without accounting for the criminal exposure hands the government sworn admissions for free.

Explaining the NPI use to an investigator. An owner who says the APRN "was fine with it" has made a statement that, if the provider says otherwise, becomes a standalone charge under 18 U.S.C. § 1001.

Fixing the records. Backfilling prescriber orders, regenerating logs, or reconstructing purchase documentation after an inspection is obstruction under 18 U.S.C. § 1519, a twenty-year felony that has sunk otherwise defensible cases.

Assuming cash-pay means no federal interest. FDA's jurisdiction does not depend on who paid. The drug crossing state or national lines is the hook.

"Backfilling prescriber orders, regenerating logs, or reconstructing purchase documentation after an inspection is obstruction under 18 U.S.C. § 1519, a twenty-year felony that has sunk otherwise defensible cases."— Aaron M. Cohen, AMC Defense Law

Where the Defense Work Actually Happens

The defensible ground here is real. Many peptide suppliers present convincing credentials, and a clinic that documented its verification effort before the shipment has a good-faith argument on the § 333(a)(2) intent element. Standing orders, collaborative practice agreements, and delegated ordering authority are legitimate structures, and where they were papered in advance the NPI allegation looks very different than where they were papered afterward. The word "afterward" is doing all the work in that sentence.

This is pre-indictment defense work, and the window is narrower than it looks. A federal investigation defense lawyer engaged now can determine whether the owners are witnesses, subjects, or targets, respond to a federal grand jury subpoena on scope rather than by dumping the file, put the clinic's own sourcing and authorization records in front of the government before agents build the timeline themselves, and press the Dubin argument while charging decisions are still fluid. After indictment, § 1028A is on the paper and the two consecutive years are in every plea discussion.

Common Questions

Facing a Board Inspection, a Drug Sourcing Inquiry, or a Federal Investigation of Your Practice?

AMC Defense Law represents med spa owners, physicians, medical directors, nurse practitioners, physician assistants, and management entities in federal investigations and prosecutions involving compounded drugs, peptides, prescriber authority, drug sourcing, and health care fraud. The firm's South Florida federal criminal defense practice is based in Boca Raton and handles matters throughout Florida and nationwide. If a board notice, a subpoena, an FDA inquiry, or a target letter has reached your clinic, speak with a federal criminal defense attorney before you respond.

Pre-indictment defense determines whether the owners are witnesses, subjects, or targets, and presses the Dubin argument while charging decisions are still fluid.

If you or your loved ones have been arrested or contacted about a federal investigation involving your clinic, call Aaron M. Cohen, 24 hours a day, for a confidential consultation to get help.

This article is for general informational purposes only and does not constitute legal advice. Reading it does not create an attorney-client relationship. The allegations described are unproven, and every case is different. If you are facing an investigation or criminal charges, consult a qualified attorney about your specific situation.

About the author: Aaron M. Cohen, Esq. is the founding attorney of AMC Defense Law (The Law Offices of Aaron M. Cohen, P.A.), a criminal defense firm based in Boca Raton, Florida. With more than 30 years of experience, Mr. Cohen represents individuals and entities in complex federal and state criminal investigations and prosecutions nationwide. He is admitted to practice law in Florida, New York, New Jersey, and the District of Columbia, and in the United States District Courts for the Southern, Middle, and Northern Districts of Florida, the District of Columbia, the Southern and Eastern Districts of New York, and the District of New Jersey. He is available pro hac vice in federal districts nationwide.